Sponsored by:

Video from SNMMI: Phillip Kuo on new Alzheimer’s disease imaging guidelines

Will Morton, Associate Editor, AuntMinnie.com. Headshot
Will Morton
Jun 22, 2025

NEW ORLEANS -- In an interview at the Society of Nuclear Medicine and Molecular Imaging annual meeting, Phillip Kuo, MD, PhD, of the City of Hope in Duarte, CA, discussed new appropriate use criteria for amyloid and tau PET imaging in Alzheimer’s disease patients.

Latest in Molecular Imaging
Breast Cancer Social
FDG-PET predicts outcomes in metastatic breast cancer
April 16, 2026
Molecular Imaging News Platform: trends, insights, professional views.
Sponsored
Molecular Imaging News Platform: trends, insights, professional views.
April 14, 2026
A Ibrain
Telix doses first patient in glioblastoma trial
April 15, 2026
Business Deal Handshake
Telix and Regeneron enter $2.1B partnership
April 14, 2026
Related Stories
Quality
Risk Management
SNMMI: For PET drugs, sterility assurance bests sterility testing
SNMMI President Jean-Luc Urbain, MD, PhD
Molecular Imaging
Urbain takes helm as SNMMI president
Ad
Molecular Imaging
Study highlights clinical potential of tau PET scans
Molecular Imaging News Platform: trends, insights, professional views.
Sponsor Content
Molecular Imaging News Platform: trends, insights, professional views.
More in Molecular Imaging
FDG-PET predicts outcomes in metastatic breast cancer
By Will Morton
Patients without disease progression on FDG-PET scans 14 days after treatment had better progression-free and overall survival.
April 16, 2026
Breast Cancer Social
Type of cardiac imaging before revascularization has shifted sharply
By Kate Madden Yee
Demographic disparities reveal modality-specific patterns, "underscoring the need for targeted interventions," researchers wrote.
April 16, 2026
Artery Heart 3 D Base Thumbnail
Telix doses first patient in glioblastoma trial
By AuntMinnie.com staff writers
The patient was dosed at Austin Health in Melbourne, Australia.
April 15, 2026
A Ibrain
Telix and Regeneron enter $2.1B partnership
By AuntMinnie.com staff writers
Regeneron to enter targeted radiopharmaceuticals sphere.
April 14, 2026
Business Deal Handshake
ARRS: Do GLP-1 drugs confound FDG-PET imaging scans?
By Will Morton
No significant differences in FDG uptake were observed in the skeletal muscle, liver, blood pool, or abdominal fat following GLP-1 agonist therapy.
April 13, 2026
Patient Pet
ARRS: MBI has considerations for streamlining breast imaging workflows
By Amerigo Allegretto
An ARRS presentation addressed how MBI workflows can be streamlined.
April 13, 2026
Screenshot (127)
New PET tracer shows promise in dementia
By Will Morton
SV2A PET may offer a robust, sensitive biomarker for disease staging, treatment monitoring.
April 10, 2026
(A) Averaged parametric images of F-18 SynVesT-1 BPND values and (B) F-18 FDG SUVR (60–90 minutes) values overlaid on anatomical (T1) images in MNI space show group differences between behavioral variant frontotemporal dementia (top) and healthy controls (middle). The color scale represents (A) BPND and (B) SUVR values. On the bottom, average z-score maps were generated to visualize regional reductions in F-18 SynVesT-1 BPND and F-18 FDG SUVR in bvFTD relative to healthy controls. For each voxel, z-scores were calculated as z = (bvFTD−meanHC )/SDHC. Negative z-scores indicate lower synaptic density or glucose metabolism in the bvFTD compared with controls in the regions. BPND, non-displaceable binding potential; bvFTD, behavioral variant frontotemporal dementia; F-18 FDG, F-18 fluorodeoxyglucose; MNI, Montreal Neurological Institute; SUVR, standardized uptake value ratio.
FDA accepts Telix NDA for glioma PET agent Pixclara
By AuntMinnie.com staff writers
The NDA resubmission included additional data and statistical analysis requested by the U.S. FDA.
April 10, 2026
Pet Brain Scan Adobe Michael dim5r Awl G7
PET links brain metabolism to survival in lung cancer patients
By Will Morton
Low brain metabolic activity was associated with increased mortality in patients with advanced NSCLC.
April 9, 2026
A visual abstract of the study
Shine receives $263M conditional loan for Mo-99 isotope facility
By AuntMinnie.com staff writers
Shine has received a conditional loan from the U.S. DOE to complete the Chrysalis medical isotope production facility for Mo-99.
April 9, 2026
Chrysalis, Shine’s large-scale irradiation facility, will complement the existing supply chain with the goal of ensuring a sustainable and reliable source of isotopes, including Mo-99.
First patients treated in RYZ401 radiopharmaceutical trial
By AuntMinnie.com staff writers
RYZ401 is an investigational actinium-225 (AC-225)-based radiopharmaceutical targeting somatostatin receptors in neuroendocrine tumors.
April 8, 2026
Atom Molecule
New method decouples Alzheimer's disease pathology at PET
By Liz Carey
AI-derived scoring tool shows independent associations, according to researchers.
April 7, 2026
Adversarial decomposition learning (ADL) enables intuitive, longitudinal visualization of disease progression and treatment response, supporting clinician–artificial intelligence collaboration. (A) Images in a 48-year-old female patient who presented with mild cognitive impairment. The ADL probability maps highlighted occipital-temporal amyloid β (Aβ) spread and focal left-temporal tau pathologic abnormalities. An area of increased occipital AV45 uptake is shown (arrowhead). (B) Images in a 51-year-old male who presented with memory decline. For each image grid, the left side is the decoupler-output AD pathologic probability map, the upper right side is the original Aβ/tau PET image, and the lower right side is the image after AD component removal by the decoupler.
Page 1 of 624
Next Page